Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency

Mark D. Schluchter, James K. Stoller, Alan F. Barker, A. Sonia Buist, Ronald Crystal, James F. Donohue, Robert J. Fallat, Gerard M. Turino, Carol E. Vreim, Margaret C. Wu

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

We examined the feasibility of a randomized clinical trial of intravenous augmentation therapy for individuals with alpha 1-antitrypsin (α1AT) deficiency, basing calculations on newly available data obtained from the NHLBI Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin. Using rate of FEV1 decline as the primary outcome and adjusting for noncompliance, a study of subjects with Stage II chronic obstructive pulmonary disease (COPD) (initial FEV1 35 to 49% predicted) with biannual spirometry measures obtained over 4 yr of follow-up would require 147 subjects per treatment arm to detect a difference in FEV1 decline of 23 ml/yr (i.e., a 28% reduction), the difference observed in the NHLBI Registry (1-sided test, α = 0.05, 90% power). To detect a 40% reduction in mortality in a 5-year study of subjects with baseline FEV1 35 to 49% predicted, recruited over the first 2 yr and then followed an additional 3 yr, 342 subjects per treatment arm would be needed. Though significant impediments to carrying out a clinical trial exist, including the cost of such a trial and the potential difficulties in recruiting patients for a placebo-controlled trial, we recommend a randomized controlled trial as the best method to evaluate the efficacy of intravenous augmentation therapy and of possible future treatments.

Original languageEnglish
Pages (from-to)796-801
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume161
Issue number3 I
Publication statusPublished - 6 Apr 2000
Externally publishedYes

Fingerprint

Clinical Trials
alpha 1-Antitrypsin Deficiency
National Heart, Lung, and Blood Institute (U.S.)
Registries
Randomized Controlled Trials
Therapeutics
Spirometry
Chronic Obstructive Pulmonary Disease
Placebos
Costs and Cost Analysis
Mortality
Autosomal Recessive alpha-1-Antitrypsin Deficiency

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Schluchter, M. D., Stoller, J. K., Barker, A. F., Buist, A. S., Crystal, R., Donohue, J. F., ... Wu, M. C. (2000). Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine, 161(3 I), 796-801.

Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency. / Schluchter, Mark D.; Stoller, James K.; Barker, Alan F.; Buist, A. Sonia; Crystal, Ronald; Donohue, James F.; Fallat, Robert J.; Turino, Gerard M.; Vreim, Carol E.; Wu, Margaret C.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 161, No. 3 I, 06.04.2000, p. 796-801.

Research output: Contribution to journalArticle

Schluchter, MD, Stoller, JK, Barker, AF, Buist, AS, Crystal, R, Donohue, JF, Fallat, RJ, Turino, GM, Vreim, CE & Wu, MC 2000, 'Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency', American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 3 I, pp. 796-801.
Schluchter, Mark D. ; Stoller, James K. ; Barker, Alan F. ; Buist, A. Sonia ; Crystal, Ronald ; Donohue, James F. ; Fallat, Robert J. ; Turino, Gerard M. ; Vreim, Carol E. ; Wu, Margaret C. / Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency. In: American Journal of Respiratory and Critical Care Medicine. 2000 ; Vol. 161, No. 3 I. pp. 796-801.
@article{6f19bd21748c492fbada90fac4d841c9,
title = "Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency",
abstract = "We examined the feasibility of a randomized clinical trial of intravenous augmentation therapy for individuals with alpha 1-antitrypsin (α1AT) deficiency, basing calculations on newly available data obtained from the NHLBI Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin. Using rate of FEV1 decline as the primary outcome and adjusting for noncompliance, a study of subjects with Stage II chronic obstructive pulmonary disease (COPD) (initial FEV1 35 to 49{\%} predicted) with biannual spirometry measures obtained over 4 yr of follow-up would require 147 subjects per treatment arm to detect a difference in FEV1 decline of 23 ml/yr (i.e., a 28{\%} reduction), the difference observed in the NHLBI Registry (1-sided test, α = 0.05, 90{\%} power). To detect a 40{\%} reduction in mortality in a 5-year study of subjects with baseline FEV1 35 to 49{\%} predicted, recruited over the first 2 yr and then followed an additional 3 yr, 342 subjects per treatment arm would be needed. Though significant impediments to carrying out a clinical trial exist, including the cost of such a trial and the potential difficulties in recruiting patients for a placebo-controlled trial, we recommend a randomized controlled trial as the best method to evaluate the efficacy of intravenous augmentation therapy and of possible future treatments.",
author = "Schluchter, {Mark D.} and Stoller, {James K.} and Barker, {Alan F.} and Buist, {A. Sonia} and Ronald Crystal and Donohue, {James F.} and Fallat, {Robert J.} and Turino, {Gerard M.} and Vreim, {Carol E.} and Wu, {Margaret C.}",
year = "2000",
month = "4",
day = "6",
language = "English",
volume = "161",
pages = "796--801",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - Feasibility of a clinical trial of augmentation therapy for α1- antitrypsin deficiency

AU - Schluchter, Mark D.

AU - Stoller, James K.

AU - Barker, Alan F.

AU - Buist, A. Sonia

AU - Crystal, Ronald

AU - Donohue, James F.

AU - Fallat, Robert J.

AU - Turino, Gerard M.

AU - Vreim, Carol E.

AU - Wu, Margaret C.

PY - 2000/4/6

Y1 - 2000/4/6

N2 - We examined the feasibility of a randomized clinical trial of intravenous augmentation therapy for individuals with alpha 1-antitrypsin (α1AT) deficiency, basing calculations on newly available data obtained from the NHLBI Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin. Using rate of FEV1 decline as the primary outcome and adjusting for noncompliance, a study of subjects with Stage II chronic obstructive pulmonary disease (COPD) (initial FEV1 35 to 49% predicted) with biannual spirometry measures obtained over 4 yr of follow-up would require 147 subjects per treatment arm to detect a difference in FEV1 decline of 23 ml/yr (i.e., a 28% reduction), the difference observed in the NHLBI Registry (1-sided test, α = 0.05, 90% power). To detect a 40% reduction in mortality in a 5-year study of subjects with baseline FEV1 35 to 49% predicted, recruited over the first 2 yr and then followed an additional 3 yr, 342 subjects per treatment arm would be needed. Though significant impediments to carrying out a clinical trial exist, including the cost of such a trial and the potential difficulties in recruiting patients for a placebo-controlled trial, we recommend a randomized controlled trial as the best method to evaluate the efficacy of intravenous augmentation therapy and of possible future treatments.

AB - We examined the feasibility of a randomized clinical trial of intravenous augmentation therapy for individuals with alpha 1-antitrypsin (α1AT) deficiency, basing calculations on newly available data obtained from the NHLBI Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin. Using rate of FEV1 decline as the primary outcome and adjusting for noncompliance, a study of subjects with Stage II chronic obstructive pulmonary disease (COPD) (initial FEV1 35 to 49% predicted) with biannual spirometry measures obtained over 4 yr of follow-up would require 147 subjects per treatment arm to detect a difference in FEV1 decline of 23 ml/yr (i.e., a 28% reduction), the difference observed in the NHLBI Registry (1-sided test, α = 0.05, 90% power). To detect a 40% reduction in mortality in a 5-year study of subjects with baseline FEV1 35 to 49% predicted, recruited over the first 2 yr and then followed an additional 3 yr, 342 subjects per treatment arm would be needed. Though significant impediments to carrying out a clinical trial exist, including the cost of such a trial and the potential difficulties in recruiting patients for a placebo-controlled trial, we recommend a randomized controlled trial as the best method to evaluate the efficacy of intravenous augmentation therapy and of possible future treatments.

UR - http://www.scopus.com/inward/record.url?scp=0034066328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034066328&partnerID=8YFLogxK

M3 - Article

C2 - 10712324

AN - SCOPUS:0034066328

VL - 161

SP - 796

EP - 801

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3 I

ER -